ClinicalTrials.gg
RecruitingNCT06424327Updated Sep 24, 2026

A Registry for People With Lung Cancer

An observational study in Lung Cancer and Lung Cancer Stage I, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 108 studies in Lung Neoplasms by Memorial Sloan Kettering Cancer Center — 9 open to participants now, 20 under way, none of them phase 3. Lung Neoplasms · Memorial Sloan Kettering Cancer Center.

Planned enrollment
Largest of 30
600 · median 78
Started
2024
with 2 others
Observational
30 of 108
3 open now
Primary completion
2029-05
later than 17 of 19 live
Registered
103rd of 108
by date

Among the 108 studies in Lung Neoplasms by Memorial Sloan Kettering Cancer Center, this one has the largest planned enrollment of the 30 observational ones that give a count, is one of 3 that started in 2024, is one of 30 observational ones, reaches primary completion later than 17 of the 19 other live ones, and was the 103rd registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

9 of the 108 studies in Lung Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Lung Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

Participants will complete questionnaires before surgery, between 2 to 4 weeks after surgery, and 6 months after surgery.

03

Conditions studied

  • Lung Cancer
  • Lung Cancer Stage I

Browse trials for

Keywords

  • lung cancer
  • lung cancer stage 1
  • segmentectomy
  • Memorial Sloan Kettering Cancer Center
  • 24-127
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All study subjects will be recruited from their respective clinics (i.e., Thoracic Surgery, Pulmonary, Survivorship, etc.) at participating sites. Potential research subjects will be identified by a member of the patient's treatment team, the protocol investigator, or research team by screening patients' medical records. If eligible, the study will be discussed with each patient.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Patients suitable for segmentectomy, according to the treating surgeon
  • Clinical Stage I with suspected NSCLC, classified preoperatively based on the AJCC TNM staging manual, 9th edition o Note: Tissue diagnosis of NSCLC is not required before enrollment. A pathologic diagnosis of NSCLC may be confirmed preoperatively with , intraoperatively with frozen section, or postoperatively on final pathology

Exclusion criteria

Exclusion Criteria:

  • Actively receiving lung cancer treatment or a history of lung cancer in the previous 5 years
  • History of chemotherapy or radiation therapy for a previous lung cancer
  • Synchronous secondary cancer in the lung or elsewhere in the body at the time of surgery
  • Carcinoid tumors
  • History of other within the past 3 years, with the exception of non-melanoma skin cancer, superficial bladder cancer, and carcinoma in situ of the cervix
  • Actively receiving treatment for other malignancies
  • Cases of lobectomy in conjunction with segmentectomy from another lobe and ≥2 segmentectomies from different lobes either en bloc or separate will be excluded from the primary analysis.

    • Multi-segmental resection from the same lobe is not a criterion for exclusion.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants with Lung Cancer

    Participants undergoing planned pulmonary segmentectomy for primary lung cancer

    Other: Patient-Reported Outcomes Measurement Information System

Interventions

  • OtherPatient-Reported Outcomes Measurement Information System

    Participants-reported outcomes will be collected using the Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS is a web-based platform developed by the National Institutes of Health. Scoring is standardized on a scale from 0 to 100, with a population mean of 50 and standard deviation of 10 units. High scores mean more of the concept being measured. This study will use PROMIS surveys assessing three domains: physical function (PROMIS bank version 2.0), pain interference (PROMIS bank version 1.1), and dyspnea severity (PROMIS bank version 1.0)

    Also known as: PROMIS

06

What researchers measure

Primary outcomes

  1. Determine 3-year disease-free survival/DFS among patients undergoing pulmonary segmentectomy for lung cancer.

    DFS is measured from the date of surgery to the date of recurrence or death

    Time frame: 3 years

  2. Determine 5-year disease-free survival/DFS among patients undergoing pulmonary segmentectomy for lung cancer.

    DFS is measured from the date of surgery to the date of recurrence or death

    Time frame: 5 years

07

Study locations

20 of 20 sites recruiting
  • University of Arizona (Data Collection Only)
    Tucson, Arizona 85704, United States
    Recruiting
  • University of California San Diego (Data collection)
    San Diego, California 92103, United States
    Recruiting
    • Joshua Boys, MD · Contact858-657-7777
  • Rush University Medical Center (Data collection only)
    Chicago, Illinois 606012, United States
    Recruiting
    • Christopher Seder, MD · Contact312-738-3732
  • Endeavor Health
    Evanston, Illinois 60201, United States
    Recruiting
    • Seth Krantz, MD · Contact847-570-2868
  • Massachusetts General Hospital Cancer Center (Data Collection Only)
    Boston, Massachusetts 02114, United States
    Recruiting
    • Michael Lanuti, MD · Contact617-726-6751
  • Brigham and Women's Hospital (Data Collection Only)
    Boston, Massachusetts 02115, United States
    Recruiting
    • Paula A Ugalde Figueroa, MD · Contact617-525-7532
  • University of Michigan (Data Collection Only)
    Ann Arbor, Michigan 48109, United States
    Recruiting
    • Jules Lin, MD · Contact734-936-8857
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • David Jones, MD · Contact212-639-6428
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
    Middletown, New Jersey 07748, United States
    Recruiting
    • David Jones, MD · Contact212-639-6428
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
    Montvale, New Jersey 07645, United States
    Recruiting
    • David Jones, MD · Contact212-639-6428
  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
    Commack, New York 11725, United States
    Recruiting
    • David Jones, MD · Contact212-639-6428
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)
    Harrison, New York 10604, United States
    Recruiting
    • David Jones, MD · Contact212-639-6428
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    Recruiting
    • David Jones, MD · Contact212-639-6428
    • Yuan Liu, MD, PhD · Contact646-888-3640
    • David Jones, PhD · Principal investigator
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)
    Uniondale, New York 11553, United States
    Recruiting
    • David Jones, MD · Contact212-639-6428
  • Thomas Jefferson University Hospital (Data Collection Only)
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
  • ALLEGHENY HEALTH NETWORK (Data Collection Only)
    Pittsburgh, Pennsylvania 15212, United States
    Recruiting
    • Benny Weksler, MD · Contact412-359-6137
  • Baylor University Medical Center (Data Collection Only)
    Dallas, Texas 75246, United States
    Recruiting
  • MD Anderson Cancer Center (Data Collection Only)
    Houston, Texas 77030, United States
    Recruiting
    • David Rice, MD · Contact800-392-1611
  • University Health Network (Data Collection Only)
    Toronto, Ontario M5G 2C4, Canada
    Recruiting
  • Centre Hospitalier de l'Université de Montreal (Data Collection Only)
    Montreal, Quebec H2L 4M1, Canada
    Recruiting
    • Moishe Liberman, MD. PhD · Contact514-890-8000, ext: 26832
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for May 2029, 60 months after the start.

Of 592 non-industry observational studies under Lung Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 162. This study's planned 60 months is close to that.

Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2024
First posted
May 22, 2024
StartActual
May 15, 2024
Primary completionEst.
May 15, 2029
CompletionEst.
May 15, 2029
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06424327
Responsible party
Sponsor
First posted
May 22, 2024
Start date
May 15, 2024
Primary completion
May 15, 2029 (estimated)
Completion
May 15, 2029 (estimated)
Last update
Sep 24, 2026

Study contacts

David Jones, MD
Contact
jonesd2@mskcc.org
212-639-6428
Bernard Park, MD
Contact
parkb@mskcc.org
646-888-3346
David Jones, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion